In August, the Brazilian vice-commissioner for patents, Julio Cesar Moreira, announced that INPI was implementing new rules in order to reduce the current backlog of patent applications, which averages eight years, to three years.
In August, the Brazilian vice-commissioner for patents, Julio Cesar Moreira, announced that the Brazilian Patent and Trademark Office (INPI) was implementing new rules in order to reduce the current backlog of patent applications, which averages eight years, to three years, and minimise delays in granting patents.
The most important rule is the creation of a priority line for pharmaceutical patents. However, the creation of a priority line for patents for medications considered vital for the Brazilian government’s Unified Health System (SUS), and mentioned by Moreira in order to reduce the average time for granting, was introduced in 2008.
Resolution #191 of 2008 established the guidelines for priority examination of patent applications before INPI. Article 4 of Resolution #191 of 2008 established a priority line of examination of pharmaceutical patent applications covering drugs purchased by the SUS: “Article 4: Will be examined as a priority, as requested by the Ministry of Health, patent applications related to drugs regularly acquired by SUS.”
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.
INPI, pharmaceuticals, ANVISA, Takeda